Published in J Thyroid Res on December 06, 2012
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med (2012) 4.59
Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med (2012) 3.86
What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)? Oncology (Williston Park) (2009) 2.99
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab (2005) 1.98
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med (2008) 1.82
131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med (2008) 1.17
Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med (2008) 1.17
Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol (2009) 1.14
Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol (2008) 1.07
Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol (2007) 1.06
Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab (2009) 1.06
Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid (2010) 0.98
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab (2009) 0.96
Contemporary post surgical management of differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) (2010) 0.94
Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid (2012) 0.92
Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging (2008) 0.91
Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab (2003) 0.90
Heath-related quality of life in thyroid cancer patients following radioiodine ablation. Health Qual Life Outcomes (2011) 0.89
Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab (2005) 0.81
Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients. Thyroid (2010) 0.80
Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods. Nucl Med Commun (2011) 0.79
Outpatient thyroid remnant ablation using repeated low 131-iodine activities (740 MBq/20 mCix2) in patients with low-risk differentiated thyroid cancer. J Clin Endocrinol Metab (2012) 0.79
Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients. Am J Clin Oncol (2012) 0.79
Protocol for thyroid remnant ablation after recombinant TSH in thyroid carcinoma. Medicina (B Aires) (2009) 0.78
Recombinant human TSH: the Argentinean experience. Thyroid (2009) 0.78
Optimum recombinant human thyrotropin dose in patients with differentiated thyroid carcinoma and end-stage renal disease. Endocr Pract (2008) 0.77
Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma. Medicina (B Aires) (2006) 0.77
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging (2010) 1.61
Biochemical persistence in thyroid cancer: is there anything to worry about? Endocrine (2013) 1.50
Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid (2008) 1.29
No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2009) 1.18
[Life support limitation at three pediatric intensive care units in southern Brazil]. J Pediatr (Rio J) (2005) 1.17
Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol (2009) 1.14
Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord (2009) 1.07
Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord (2010) 0.99
Prevalence of thyroid autoimmunity in patients with pemphigus vulgaris. Medicina (B Aires) (2005) 0.88
The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clin Chem Lab Med (2015) 0.85
Long-term Prognosis in COPD Exacerbation: Role of Biomarkers, Clinical Variables and Exacerbation Type. COPD (2014) 0.84
Lymphatic mapping using SPECT/CT in vulvar carcinoma. Clin Nucl Med (2010) 0.84
Latin American thyroid society recommendations for the management of thyroid nodules. Arq Bras Endocrinol Metabol (2009) 0.82
Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer. Clin Nucl Med (2014) 0.81
Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma. J Clin Endocrinol Metab (2013) 0.81
The association of insulin resistance with subclinical thyrotoxicosis. Thyroid (2011) 0.80
Outpatient thyroid remnant ablation using repeated low 131-iodine activities (740 MBq/20 mCix2) in patients with low-risk differentiated thyroid cancer. J Clin Endocrinol Metab (2012) 0.79
Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods. Nucl Med Commun (2011) 0.79
Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions. J Nucl Med (2013) 0.79
Protocol for thyroid remnant ablation after recombinant TSH in thyroid carcinoma. Medicina (B Aires) (2009) 0.78
Recombinant human TSH: the Argentinean experience. Thyroid (2009) 0.78
Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma. Medicina (B Aires) (2006) 0.77
Frequency of pancreatic beta-cell autoimmunity markers in patients with autoimmune thyroid disease. Medicina (B Aires) (2008) 0.77
Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH? Eur J Nucl Med Mol Imaging (2004) 0.77
Optimum recombinant human thyrotropin dose in patients with differentiated thyroid carcinoma and end-stage renal disease. Endocr Pract (2008) 0.77
Undetectable pre-ablation thyroglobulin levels in patients with differentiated thyroid cancer: it is not always what it seems. Arq Bras Endocrinol Metabol (2013) 0.76
Thyroglossal duct cyst with papillary carcinoma. Thyroid (2004) 0.75
Thyroid cancer: does the size matter? Thyroid (2008) 0.75
Resolution of Cushing's syndrome and exacerbation of autoimmune thyroiditis. Thyroid (2011) 0.75
Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer. Endocrine (2014) 0.75
Iodine intake in Argentina. Thyroid (2006) 0.75
Fatal outcome of a young woman with papillary thyroid carcinoma and graves' disease: possible implication of "cross-signalling" mechanism. Arq Bras Endocrinol Metabol (2008) 0.75
Patients with familial non-medullary thyroid cancer have an outcome similar to that of patients with sporadic papillary thyroid tumors. Arq Bras Endocrinol Metabol (2011) 0.75
High prevalence of thyroid disorders in relatives of patients with familial papillary thyroid cancer. Medicina (B Aires) (2010) 0.75
[Papillary thyroid microcarcinoma diagnosed based on cyst-like mediastinal metastasis]. Endocrinol Nutr (2012) 0.75
Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal. Q J Nucl Med Mol Imaging (2015) 0.75
Tumour growth after recombinant human TSH. Clin Endocrinol (Oxf) (2002) 0.75
Detectability of hypervascularity in early dynamic PET depends on tracer kinetics: 18 F-FDG versus 68 Ga-DOTATOC in hepatic NET metastasis. Liver Int (2013) 0.75
High prevalence of thyroid nodules in patients with achrocordons (skin tags). Possible role of insulin-resistance. Medicina (B Aires) (2009) 0.75
Lack of increase in the serum thyroid-stimulating hormone level after intramuscular administration of recombinant human thyroid-stimulating hormone doses in a morbidly obese patient. Endocr Pract (2011) 0.75
Low-activity 124I-PET/low-dose CT versus 99mTc-pertechnetate planar scintigraphy or 99mTc-pertechnetate single-photon emission computed tomography of the thyroid: a pilot comparison. Clin Nucl Med (2013) 0.75